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ADAMTS = a disintegrin and metalloproteinase with thrombospondin motifs; bp = base pairs; HDAC = histone deacetylase; MMP = matrix metallo-
proteinase; TIMP = tissue inhibitor of metalloproteinases.
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Abstract
Increased expression of metalloproteinases is a fundamental aspect
of arthritis pathology and its control is a major therapeutic objective.
In cartilage cultured in the presence of the cytokines interleukin-1
and oncostatin M, chondrocytes produce enhanced levels of
metalloproteinases of the ADAMTS (a disintegrin and
metalloproteinase with thrombospondin motifs) and MMP (matrix
metalloproteinase) families, resulting in the degradation of aggrecan
and collagen. The histone deacetylase inhibitors trichostatin A and
butyrate were shown to drastically reduce expression of these
enzymes relatively selectively, with concomitant inhibition of
breakdown of matrix components. This family of enzymes is
therefore a promising target for therapeutic intervention.
Proteolytic activity in articular cartilage is central to joint
destruction in arthritis. Proteinase expression is well known to
be modulated by cytokines, intracellular signaling, and
transcription factor action, but recent work by Young and
colleagues [1] indicates that there is significantly more to this
process than has been generally believed.
The human genome is packed in a matrix of histones that
shield it from transcription by RNA polymerase II. The basic
unit of chromatin is the nucleosome core particle, which
consists of 147 bp of DNA wound 1.7 times around a histone
octamer composed of two copies each of four histone
partners (H2A, H2B, H3, and H4). The core particles are
separated by a 10- to 60-bp linker region and the resulting
‘beads-on-a-string’ are further condensed into thicker fibers,
which make up chromatin [2].
While structural studies suggested the nucleosome to be a
stable particle, it is now clear that in vivo it is much more
dynamic [3]; histone units can be exchanged and the whole
complex is able to slide along the DNA in an ATP-dependent
mechanism through the action of members of the Swi2/Snf2
family of ATPases. In addition to a conserved globular core
protein region, each histone molecule contains an N-terminal
tail rich in basic residues, which project beyond the
surrounding DNA. In the case of H3 and H4, specific lysine
sidechains undergo acetylation, through the action of histone
acetyltransferases, by way of acetyl coenzyme A, a step
which is associated with transcriptional activation. These
modifications can be reversed by histone deacetylases
(HDACs), of which there are four families [4].
Three of the families (I, II, and IV) are zinc-dependent enzymes,
catalytically resembling the metalloproteinases, but family III
(the recently discover SIR2 enzymes) uses a completely
different mechanism depending on NAD+ (oxidized
nicotinamide-adenine dinucleotide) as a cofactor [5]. The
members of family II are of particular importance because they
are modular proteins with binding domains for protein–protein
interaction with, among others, transcription factors.
The specific roles of various HDACs have been investigated
by gene deletion in mice. Of special interest with regard to
cartilage and bone development is the recently determined
phenotype of the HDAC4-null animals [6]. HDAC4 is
expressed in prehypertrophic chondrocytes and interacts
with the key transcription factor Runx2 (also termed Cbfa1).
The null animals develop ectopic calcification and early-onset
chondrocyte hypertrophy, as is also seen in mice
constitutively expressing Runx2. Conversely, mice over-
expressing HDAC4 in cartilage show greatly reduced
chondrocyte hypertrophy, similar to that in the Runx2-null
phenotype.
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In a more general way, the role of the HDACs can be
investigated using inhibitors. HDACs of families I, II, and IV
are inhibited by hydroxamate derivatives such as the natural
product trichostatin A [7]. Although at the moment such
HDAC inhibitors show little specificity for individual HDAC
family members [8], efforts have been made to develop
specific small-molecule inhibitors, and various compounds
are currently in clinical trials for various forms of cancer [9].
Butyrate has long been known to be an effective HDAC
inhibitor and is currently in phase II clinical trials [9]. Initial
evidence also points to the use of HDAC inhibitors in
inflammatory arthritis [10,11].
HDACs show a varied tissue distribution, and mapping of
cartilage transcripts shows evidence for expression of many
HDACs in this tissue [12]. The recent work from Young and
colleagues [1] shows the effective use of HDAC inhibitors for
decreasing metalloproteinase expression in cartilage and
demonstrates that the paradigm of inhibition of histone
deacetylation leading to gene silencing is not absolute.
Cawston and colleagues showed many years ago that
cartilage cultured in the presence of a mixture of the
cytokines interleukin-1 and oncostatin M undergoes rapid
aggrecan loss followed later by collagen degradation and the
release of degraded collagen fragments into the medium
[13]. These degradative processes have been attributed to
the action of specific ADAMTS (a disintegrin and metallo-
proteinase with thrombospondin motifs) family members and
matrix metalloproteinase 13 (MMP13 or collagenase 3),
respectively. Addition of either trichostatin A or butyrate
resulted in a dramatic reduction of glycosaminoglycan loss
(aggrecan degradation) and collagen release. These
processes are associated with decreased levels of ADAMTS-
4 and -5 and of MMP13, respectively, and message levels of
these gene products were correspondingly reduced as
determined by real-time polymerase chain reaction. In
contrast, expression of the major cartilage structural
molecules aggrecan and type II collagen and a number of
other metalloproteinases was unaffected by the presence of
the inhibitors. The findings using bovine nasal cartilage were
reinforced by cell culture studies using a human chondro-
sarcoma cell line and primary human chondrocytes.
In a second paper [14], Young and colleagues address the
other side of metalloproteinase action, the expression of the
inhibitor TIMP (tissue inhibitor of metalloproteinases). Here
they show that HDAC inhibitors have opposing effects on
TIMP-1 expression, depending on whether phorbol ester or
transforming growth factor β is used for induction, with the
latter showing an impressive repression with HDAC inhibitors
whereas the phorbol ester increases TIMP-1 expression.
Conclusion
Both of these studies by Young and colleagues [1,14]
suggest the potential for HDAC inhibitors in the control of
cartilage catabolism and demonstrate that more work is
required to understand the molecular mechanisms underlying
their action and in the regulation of these enzymes.
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